ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can't
If a record IPO wasn’t enough to put RemeGen on the map, perhaps a deal with Seagen — sporting $200 million in cash — might.
At the center of the licensing pact is disitamab vedotin, an anti-HER2 antibody-drug conjugate that will slide directly into Seagen’s pipeline, except in certain Asian countries where China-based RemeGen will be keeping development and commercialization rights.
The fellow ADC specialists have been following each other for quite a while, RemeGen CEO Jianmin Fang tells me, as his trans-Pacific team leveraged Seagen’s linker technology and kept it posted on clinical data. It just happens to be the right time to pull the trigger.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.